American CryoStem Corporation

Raising 1M; complete current post-concussion syndrome IND, New Long Covid, IND filing / Walter Reed Military Hospital, Bethesda, Md. accepted by FDA

Facebook Twitter LinkedIn

American CryoStem Corporation is a clinical-stage therapeutics developer delivering autologous regenerative therapeutics and advanced tissue treatments harnessing the power of mesenchymal stem cells (MSCs) and adipose tissue.  The Company has completed its preclinical animal studies and a preclinical human pilot study, (87 patients and 154 treatments) targeting numerous indications. In 2020 we received approval for our first US Investigational New Drug (IND) for Post -Concussion Syndrome (currently ongoing)  and have developed additional studies utilizing our validated platform to be filed with the US FDA in 2022 .   Additional, IND filing accepted by FDA this week, awaiting review – LONG COVID study with Walter Reed Military Hospital, Bethesda Md. 
Power Point available, John Arnone 732-310-3099

Ready to Ask For Funding for your company?

Post a Funding Request